FDA warns Vietnam seafood processor Duong Ha over HACCP failures for frozen scombrotoxin-forming fish.
What happened
FDA inspected the seafood processing facility in Vietnam on July 8 through 9, 2024, and found deviations from the seafood HACCP regulation for frozen raw vacuum-packaged scombrotoxin-forming fish. FDA issued a Form FDA 483 listing the deviations. The company responded on July 19 and September 16, 2024, but FDA said its review showed continuing serious concerns with the HACCP program.
What FDA found
The HACCP plan for frozen fish fillets did not list a critical control point for unrefrigerated processing to control histamine formation.
21 CFR 123.6(a) and (c)(2)The plan did not set a critical limit for internal fish temperature when fish are off-loaded from the harvest vessel to control histamine formation.
21 CFR 123.6(c)(3)The plan’s critical limit for Clostridium botulinum was inadequate, and FDA recommends finished products contain a “keep frozen” statement.
21 CFR 123.6(c)(3)The plan’s monitoring procedures for histamine at critical control points were inadequate.
21 CFR 123.6(c)(4)The monitoring record did not provide spaces for documenting which units were examined or the individual observations for ice adequacy, histamine testing, or sensory examination.
21 CFR 123.6(c)(7)The corrective actions at a critical control point did not ensure that affected product would be kept out of commerce or that the cause of the deviation would be corrected.
21 CFR 123.7(b)
What FDA wants
FDA tells the company to respond in writing within 15 working days with specific corrections and documentation, including a revised hazard analysis and HACCP plan and five consecutive days of completed monitoring records. If corrections cannot be completed in that time, the company must explain the delay and state when it will correct remaining violations.
Who should pay attention
- US importers of frozen seafood from Vietnam
- brands selling frozen fish fillets
- seafood processors handling scombrotoxin-forming fish
This is a summary. Read the original letter on fda.gov.